MétaCan
Menu
Back to cohort
Record W2147048440 · doi:10.1212/wnl.0b013e318228bf11

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

2011· article· en· W2147048440 on OpenAlexfundno aff
Mary Sano, Karen L. Bell, Douglas Galasko, James E. Galvin, Ronald G. Thomas, C H van Dyck, Paul Aisen

Bibliographic record

VenueNeurology · 2011
Typearticle
Languageen
FieldMedicine
TopicLipoproteins and Cardiovascular Health
Canadian institutionsnot available
FundersNational Institute of Neurological Disorders and StrokeNational Institute of Mental HealthHealth Sciences, University of ArizonaNational Institute on AgingMedical Center, University of RochesterUniversity of California, IrvineUniversity of California, San DiegoUniversity of California, DavisMitsubishi Tanabe Pharma CorporationElanAstraZenecaGenentechUniversity of OxfordBaxter InternationalLewy Body Dementia AssociationNational Center for Research ResourcesNational Alliance for Research on Schizophrenia and DepressionMyriad GeneticsSUNY Downstate Medical CenterMarinus PharmaceuticalsGeorgetown UniversityDemensförbundetOtsuka PharmaceuticalNational Institutes of HealthBioMarin PharmaceuticalAvid RadiopharmaceuticalsUniversity of PittsburghUniversity of California, Los AngelesPfizerUniversity of WashingtonU.S. Department of DefenseAmerican Health Assistance FoundationEli Lilly and CompanyState University of New YorkUniversity of PennsylvaniaUniversity of South CarolinaAstellas PharmaUniversity of Southern CaliforniaEisaiMedpaceBrown UniversityDaiichi Sankyo EuropeYale UniversityAstellas Foundation for Research on Metabolic DisordersDainippon Sumitomo PharmaEmory UniversityAlzheimer's AssociationBrigham and Women's HospitalYork UniversityUniversity of RochesterNorthwestern UniversityGlaxoSmithKlineShireForest LaboratoriesBristol-Myers SquibbSanofiCase Western Reserve UniversityAmerican Federation for Aging ResearchRush UniversityAmgen
KeywordsSimvastatinMedicinePlaceboRandomized controlled trialDouble blindAlzheimer's diseaseDiseaseInternal medicinePathologyAlternative medicine

Abstract

fetched live from OpenAlex

Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG - CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, supporting the hypothesis that statin therapy is useful in the treatment of AD. Objective: To determine if the lipid-lowering agent simvastatin slows the progression of symptoms in AD. Methods: This randomized, double-blind, placebo-controlled trial of simvastatin was conducted in individuals with mild to moderate AD and normal lipid levels. Participants were randomly assigned to receive simvastatin, 20 mg/day, for 6 weeks then 40 mg per day for the remainder of 18 months or identical placebo. The primary outcome was the rate of change in the Alzheimer's Disease Assessment Scale–cognitive portion (ADAS-Cog). Secondary outcomes measured clinical global change, cognition, function, and behavior. Results: A total of 406 individuals were randomized: 204 to simvastatin and 202 to placebo. Simvastatin lowered lipid levels but had no effect on change in ADAS-Cog score or the secondary outcome measures. There was no evidence of increased adverse events with simvastatin treatment. Conclusion: Simvastatin had no benefit on the progression of symptoms in individuals with mild to moderate AD despite significant lowering of cholesterol. Classification of evidence: This study provides Class I evidence that simvastatin 40 mg/day does not slow decline on the ADAS-Cog. Aβ= : amyloid β peptide; AChE= : acetylcholinesterase; AD= : Alzheimer disease; ADAS-Cog= : Alzheimer's Disease Assessment Scale–cognitive portion; ADCS= : Alzheimer's Disease Cooperative Study; ADCS-ADL= : Alzheimer's Disease Cooperative Study Activities of Daily Living; ADCS-CGIC= : Alzheimer's Disease Cooperative Study Clinical Global Impression of Change; ADCS-RUI= : Alzheimer's Disease Cooperative Study Resource Use Instrument; ALT= : alanine aminotransferase; AST= : aspartate aminotransferase; ATP= : Adult Treatment Panel; CRP= : C-reactive protein; GEE= : generalized estimating equation; HDL= : high-density lipoprotein; HMG-CoA= : 3-hydroxy-3-methylglutaryl coenzyme A; ITT= : intent-to-treat; LDL= : low-density lipoprotein; MMSE= : Mini-Mental State Examination; NPI= : Neuropsychiatric Inventory; QOL= : quality of life

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.042

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.004
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0050.002
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0130.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.053
GPT teacher head0.305
Teacher spread0.252 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations329
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicLipoproteins and Cardiovascular HealthFrench-language works237,207